ARGNF (argenx SE) Marketable Securities : $1,879 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is argenx SE Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. argenx SE's Marketable Securities for the quarter that ended in Dec. 2024 was $1,879 Mil.

argenx SE's annual Marketable Securities declined from Dec. 2022 ($1,392 Mil) to Dec. 2023 ($1,131 Mil) but then increased from Dec. 2023 ($1,131 Mil) to Dec. 2024 ($1,879 Mil).

argenx SE Marketable Securities Historical Data

The historical data trend for argenx SE's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Marketable Securities Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

779.65

1,002.05

1,391.81

1,131.00

1,878.89

argenx SE Quarterly Data
	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Marketable Securities	Get a 7-Day Free Trial															1,131.00	-	1,664.10	-	1,878.89

argenx SE Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

argenx SE (OTCPK:ARGNF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

argenx SE Marketable Securities Related Terms

Thank you for viewing the detailed overview of argenx SE's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (OTCPK:ARGNF) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.